Editorially reviewed · Last updated September 8, 2026 · How we review
Key findings
- TB-500 is not FDA approved; the retrieved meeting materials do not verify the reported 8–6–1 vote.
- FDA’s review describes an acetylated seven-amino-acid fragment of thymosin beta-4 and warns of inconsistent product identity.
- The review found no human effectiveness or safety evidence for the reviewed use and does not establish a human dosing regimen.
- Compounding eligibility, an advisory recommendation and drug approval are different decisions.
TB-500: The FDA 503A Vote, Legality, and What the Evidence Actually Shows
The TB-500 Vote: What Actually Happened
The retrieved agenda and briefing establish the question and the staff recommendation. They do not establish a committee vote tally or the reasoning of individual voters. Those require the final minutes or a verified meeting record.
Eligible Does Not Mean Legal
A Pharmacy Compounding Advisory Committee recommendation is advice to FDA. It is not drug approval and does not itself change the 503A Bulks List.
Is TB-500 Legal Right Now?
There is no FDA-approved TB-500 product. The July advisory review does not authorize a seller’s product for human use or validate an online prescription offer.
What Is TB-500?
An important distinction the seller pages tend to blur:
| Substance | What it is | Clinical development |
|---|---|---|
| TB-500 | A synthetic seven-amino-acid fragment of thymosin beta-4 | No completed human efficacy trial for the injury-recovery use case |
| Full-length thymosin beta-4 (Tβ4) | The complete 43-amino-acid protein | Has reached Phase 2/3 — but for a topical eye drop (RGN-259, dry eye), not injected muscle recovery |
The Evidence: Animal vs Human
| Evidence type | What exists |
|---|---|
| Animal studies | Preclinical data on Tβ4 and fragments in cardiac, wound, and tissue-repair models |
| Published human RCTs | None. No completed human efficacy trial for musculoskeletal injury |
| Human effectiveness data for the reviewed use | None, per the FDA's own review |
| A cited in-vitro test | TB-500 did not induce wound healing in fibroblast cultures |
| Chemical characterization | FDA found both forms poorly characterized (naming and data gaps) |
| Long-term human safety data | Essentially none |
The FDA review does not establish a human recovery benefit. Its negative laboratory finding and missing human data should not be converted into either a treatment recommendation or a precise estimate of clinical risk.
FDA Staff Recommendation and the Unverified Vote
FDA’s written position is clear: the available evidence weighed against inclusion. The record reviewed does not establish why a committee majority might have disagreed. An advisory recommendation would not establish that TB-500 works.
Doses Circulating in the Community (No Clinical Validation)
Grey-Market Safety Risks
TB-500 vs BPC-157
TB-500 is the seven-residue thymosin beta-4 fragment discussed above; BPC-157 is a different peptide. Marketing them together does not make their evidence interchangeable.
The "Wolverine Stack"
How This Relates to GLP-1 Drugs and Retatrutide
Retatrutide has human randomized-trial evidence, while FDA’s TB-500 review found no human effectiveness data. That difference in available evidence matters; neither a shared peptide label nor marketing language establishes benefit.
Frequently Asked Questions
Did the FDA approve TB-500?
No. The 2026 FDA briefing discusses compounding eligibility and recommends against inclusion. Advisory review is not drug approval. The retrieved materials do not verify the reported vote tally or establish a final rule.
Is TB-500 legal now?
There is no FDA-approved TB-500 product. An advisory recommendation does not itself authorize compounding or make an online product suitable for human use. The sources reviewed here do not establish a new final authorization.
Is there any human evidence that TB-500 works?
No completed human efficacy trial supports TB-500 for injury or musculoskeletal recovery. The FDA's review found no human effectiveness data and cited an in-vitro study in which TB-500 did not induce wound healing. Clinical trials that people point to usually involve full-length thymosin beta-4 as a topical eye drop (RGN-259) — a different molecule and a different use.
Why did the committee vote yes if the FDA staff said no?
The retrieved agenda and briefing do not verify the vote or the reasoning of a committee majority. FDA staff recommended against inclusion because of characterization problems and missing human effectiveness and safety data.
What is the correct dose of TB-500?
The FDA review does not establish a human dose for injury recovery. Online loading and maintenance schedules are not a substitute for clinical evidence.
What is the difference between TB-500 and thymosin beta-4?
The FDA review describes TB-500 as an acetylated seven-amino-acid fragment from positions 17–23 of the 43-amino-acid thymosin beta-4 protein. Research on the full-length molecule cannot establish the safety or benefit of the fragment.
What is the Wolverine stack?
It is a nickname for combining TB-500 and BPC-157, not an approved combination. The FDA TB-500 review does not establish a safe or effective stacking regimen.
Is TB-500 safe?
Human safety is not established. FDA identified missing clinical data, inconsistent chemical identity and potential immunogenicity from aggregation or peptide impurities.
Sources
-
U.S. Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. FDA.gov meeting page
-
U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (Category 2 list). FDA.gov
-
World Anti-Doping Agency. 2026 Prohibited List (TB-500 / thymosin beta-4, Section S2). WADA
-
Related on this site: BPC-157 · The Wolverine Stack · Are Peptides Legal in 2026? · Grey-Market Peptides
- What this is
- Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
- Regulatory status
- Retatrutide and similar peptides are investigational — not approved by the FDA or any regulator. Semaglutide and tirzepatide are prescription-only medicines, available only through a licensed prescriber.
- Our standard
- Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
- No commercial ties
- We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.
Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.
Sources
NEJM
The Lancet
JAMA
FDA
ClinicalTrials.govRelated reading
BPC-157: FDA 503A Vote, Legality & Safety
An advisory vote is not FDA approval. What the FDA briefing says about BPC-157 human evidence and current compounding status.
The Wolverine Stack: BPC-157 + TB-500
No established clinical evidence for the marketed recovery combination. Peptide identity, FDA status and unresolved safety questions.
Are Peptides Legal in 2026? Inside the FDA 503A Vote Result
FDA advisory votes do not add peptides to the final compounding list. Current U.S. rules, evidence limits and GLP-1 distinctions.
Grey Market Retatrutide: Risks, Dangers, and What You Should Know
Research labels and purity claims do not establish product equivalence, approved dosing or legal exemptions.
Retatrutide Cost per Month and How to Access It
Every legitimate route to retatrutide today, open trials updated daily, Lilly's expanded access criteria, and what it may cost once approved.